Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi vs iGlar in T2DM with MASLD
NCT07274644Phase 4Active, not recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Nanjing Drum-Tower Hospital. Started Mar 2025; status: active, not recruiting.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07274644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274644.